Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Ottawa

$105,000.00

Development of an in vivo mass screen for chemicals linked to Parkinson's Disease

FY 2012-13

Summary
Parkinson's disease is a neurological disorder classified by a clinical diagnosis of movement difficulty, tremor at rest, and other fine motor control loss because of neurodegeneration in the brain. Parkinson's disease is the second most common neurological disorder, affecting 12% of all Canadians. A small percentage of patients who have Parkinson's disease have an associated genetic link, however, the vast majority of Parkinson's disease tends to affect patients over the age of 50 with no discernible cause. The zebrafish (Danio rerio) is a small freshwater fish that is commonly used in molecular biology, and as a model for human disease. Zebrafish embryos posses transparent bodies, allowing internal processes such as blood flow and brain development to be imaged externally in a convenient manner. These features make the zebrafish a strong model for performing screens of functional and anatomical changes from chemical exposures. This project will use zebrafish in a mass chemical screen for environmental and drug compounds that cause neurological damage, and cause observable motor deficiencies that could be related to Parkinson's disease. This model can also be used as a tool to screen for chemicals that can alleviate the symptoms of parkinsonism in zebrafish that have been pre-treated with neurotoxins to have deficits associated with Parkinson's disease. Changes in behavior and neuroanatomy can then be assayed, with associated investigations into the mechanism of action of each candidate compound on its effects on the progression of Parkinson's disease in affected zebrafish embryos. The end goal of this project is to establish the zebrafish as a cost-effective live animal platform for mass screening drug discovery and environmental toxicology studies, and to develop this platform into an efficient assay of neurodegeneration. With the findings from this project, we can identify potential chemicals that could help treat Parkinson's disease in the future.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
283914
Name
Keow Jonathan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of an in vivo mass screen for chemicals linked to Parkinson's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Behaviour Analysis; Mass Screen; Neurobiology; Parkinson'S Disease; Zebrafish
Abstract
Parkinson's disease is a neurological disorder classified by a clinical diagnosis of movement difficulty, tremor at rest, and other fine motor control loss because of neurodegeneration in the brain. Parkinson's disease is the second most common neurological disorder, affecting 12% of all Canadians. A small percentage of patients who have Parkinson's disease have an associated genetic link, however, the vast majority of Parkinson's disease tends to affect patients over the age of 50 with no discernible cause. The zebrafish (Danio rerio) is a small freshwater fish that is commonly used in molecular biology, and as a model for human disease. Zebrafish embryos posses transparent bodies, allowing internal processes such as blood flow and brain development to be imaged externally in a convenient manner. These features make the zebrafish a strong model for performing screens of functional and anatomical changes from chemical exposures. This project will use zebrafish in a mass chemical screen for environmental and drug compounds that cause neurological damage, and cause observable motor deficiencies that could be related to Parkinson's disease. This model can also be used as a tool to screen for chemicals that can alleviate the symptoms of parkinsonism in zebrafish that have been pre-treated with neurotoxins to have deficits associated with Parkinson's disease. Changes in behavior and neuroanatomy can then be assayed, with associated investigations into the mechanism of action of each candidate compound on its effects on the progression of Parkinson's disease in affected zebrafish embryos. The end goal of this project is to establish the zebrafish as a cost-effective live animal platform for mass screening drug discovery and environmental toxicology studies, and to develop this platform into an efficient assay of neurodegeneration. With the findings from this project, we can identify potential chemicals that could help treat Parkinson's disease in the future.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Keow, Jonathan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~